You are here

Our science / Clinical Trials / Find a Trial / NCT00265551

Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia

Back to Search Print Save as PDF Bookmark Trial

NCT00265551

Last updated on February 23, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Little Rock, Arkansas, 72201 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Schizophrenia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Clinical diagnosis of schizophrenia

- Ability to remain hospitalized for at least first 4 weeks of study

- Needs hospitalization due to worsening of schizophrenia

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Type 1 or 2 diabetes

- Previous use of clozapine

- Serious medical illness other than schizophrenia

NCT00265551
Pfizer
Completed
Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Schizoaffective Disorder, Schizophrenia
A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs
NCT00649064
All Genders
18+
Years
Multiple Sites
Schizophrenia
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
NCT01939548
All Genders
18+
Years
Multiple Sites
Schizophrenia
A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In Subjects With Schizophrenia
NCT00743847
All Genders
Schizophrenia
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers
NCT01511510
All Genders
18+
Years
New Haven, Connecticut

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now